SARS-CoV-2 vaccine, subunit (Pending FDA Approval)

Brand and Other Names:COVID-19 vaccine, subunit
  • Print
Sections

Dosing & Uses

COVID-19 Disease Prevention

Pending FDA approval for prevention of coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Several vaccines are in late phase 3 clinical trials in the United States

Next:

Pharmacology

Mechanism of Action

The goal is to elicit long-term antigen-specific antibody responses by plasma cells and to develop persistent T-cell and B-cell memory of the antigen (ie, humoral and cellular immune response)

A portion of the viral antigen is used to create the vaccine; once vaccinated, an immune response is elicted to the protein subunit

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.